Table 3.
Clinical parameters for the combined KidCOM and C3 Glomerulopathy and Membranoproliferative Glomerulonephritis: Pediatric Outcomes cohorts
| Clinical parameters | Total cohort (N = 165) | IC-MPGN (n = 42) | C3G (n = 43) | P value (IC-MPGN vs. C3G) |
|---|---|---|---|---|
| Nephrotic syndrome at diagnosis | 11.8% | 22.0% | 11.9% | NS (0.25) |
| Hypertension at diagnosis | 57.5% | 57.1% | 57.6% | NS (0.38) |
| Hypertension at last follow-up | 42.5% | 70.4% | 42.4% | NS (0.40) |
| P value | NS (0.05) | NS (0.31) | NS (0.44) | |
| Hematuria at diagnosis | 80.9% | 81.0% | 61.9% | NS (0.19) |
| Hematuria at last follow-up | 48.5% | 57.1% | 38.1% | NS (0.82) |
| P value | <0.0001a | 0.0273a | 0.0005a | |
| On antihypertensives at diagnosis | 55.6% | 70.7% | 46.3% | 0.04a |
| On antihypertensives at last follow-up | 65.0% | 71.4% | 74.4% | NS (0.81) |
| P value | NS (0.09) | NS (>0.99) | 0.01a | |
| Antihypertensives per patient at diagnosis | 2.0 (1.6–2.3) | 2.2 (1.4–3.0) | 1.3 (0.73–1.9) | NS (0.16) |
| Antihypertensives per patient at last follow-up | 1.5 (1.3–1.7) | 1.7 (1.3–2.1) | 0.86 (0.56–1.2) | NS (0.06) |
| P value | 0.01a | NS (0.19) | NS (0.14) | |
| Corticosteroids at diagnosis | 43.7% | 68.3% | 57.1% | NS (0.37) |
| Corticosteroids at last follow-up | 31.7% | 31.7% | 40.5% | NS (0.49) |
| P value | 0.049a | 0.0018a | NS (0.19) | |
| ACEi/ARB at diagnosis | 49.5% | 53.3% | 40% | NS (0.42) |
| ACEi/ARB at last follow-up | 75.0% | 76.7% | 77.8% | NS (>0.99) |
| P value | 0.0002a | NS (0.10) | 0.0036a |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; C3G, C3 glomerulopathy; IC-MPGN, immune-complex membranoproliferative glomerulonephritis; NS, not significant.
Corticosteroids include oral prednisone, oral prednisolone, or i.v. methylprednisolone. Numeric data shown as the mean with 95% confidence interval.
a
Statistically significant.